Results 191 to 200 of about 112,622 (301)

Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer. [PDF]

Front Cell Dev Biol
Wang Z, Ge Q, Aihetaimujiang A, Zhang J, Lu J, Yang J, Chen Y, Qin B, Zhang H, Xu WH, Ye D.   +10 more
europepmc   +1 more source

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. [PDF]

Sci Rep
Suresh S, McPherson L, Ford JM.
europepmc   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. [PDF]

Nucleic Acids Res
Ribeiro J, Hansen K, van Beek L, Stubbs C, Frigola J, Talbot S, Bentouati S, Hall J, Wijnhoven PWG, Armenia J, Schimpl M, Forment JV, Albertella MR, O'Connor MJ, Illuzzi G.   +14 more
europepmc   +1 more source

Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka, Hiroyuki Okada, Akira Hirasawa   +11 more
wiley   +1 more source

Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture. [PDF]

PLoS One
Soetomo SA, Sharp MF, Crismani W.
europepmc   +1 more source

Patient and Public Involvement Reporting Consistency: Analysis of 24 Clinical Practice Guidelines From 4 Countries

Clinical and Public Health Guidelines, Volume 3, Issue 2, April 2026.
ABSTRACT Objective We compared the reporting of patient and public involvement (PPI) in the development of clinical practice guidelines (CPG) with the guidance regarding PPI in the auspicing organisation's guideline development manual. Methods We examined the PPI guidance provided by seven guideline auspicing organisations from four countries, that ...
Elizabeth Ann Bryant, Rae Thomas, Sharon Lea Sanders   +2 more
wiley   +1 more source

The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. [PDF]

Cancers (Basel)
Al-Ani M, Baraka B, Mathiyalagan N, Sarwar MA, Segaran A, Abuzahra W, Radford A, Buxton K, Seneviratne L, Sundar S, Anand A, Nunns D, Williamson K, Wormald B, Gajjar K, Madhusudan S.   +15 more
europepmc   +1 more source

244 PARP inhibitors

European Journal of Cancer Supplements, 2010
openaire   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source